Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab‐Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results

Conclusion.Acceptable safety and encouraging signals of activity in patients with metastatic pancreatic cancer receiving necuparanib, nab‐paclitaxel, and gemcitabine were demonstrated.

Source: The Oncologist - December 13, 2017 Category: Cancer & Oncology Authors: Eileen M. O'Reilly, James Roach, Paul Miller, Kenneth H. Yu, Catherine Tjan, Molly Rosano, Silva Krause, William Avery, Julie Wolf, Keith Flaherty, Darrell Nix, David P. Ryan Tags: Chinese Edition, Clinical Trial Results, Gastrointestinal Cancer Source Type: research